Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

"Nordic Cold Chain launches cold chain packaging for GLP-1 drugs" was originally created and published by Packaging Gateway, ...

This is only a glimpse of the data available to CivicScience clients. Discover more data. It’s safe to say that GLP-1 ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

Here’s a roundup of numbers from the last week of HR news — including the percentage of managers who use AI to help determine ...

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

Changes in eating habits are impacting some categories, like snacks, more than others. Taking GLP-1 drugs reduces a person's appetite significantly, slowing down the emptying of the stomach and making ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...